Adults 35 to 89, any sex, with Auditory Training and Auditory Efferent System. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Magnitude of Medial Olivocochlear Reflex InhibitionPrimary· First and last measurements (baseline and last session up to a year later)
Decibel difference in medial olivocochlear reflex inhibition computed between final visit and baseline visit, where medial olivocochlear reflex inhibition is quantified as amplitude difference (in decibels) between transient-evoked otoacoustic emissions obtained with versus without broadband noise presented to the contralateral ear.
Group
Value
95% CI
Training
-0.82
-3.71 – -0.08
Control
-0.49
-1.23 – 0.49
Association Between Medial Olivocochlear Reflex Inhibition and Untrained Speech Perception TasksPrimary· Baseline (First study visit - 3 hour session)
Spearman rank correlation computed between medial olivocochlear reflex inhibition (in decibels) and performance (in percent correct) on Coordinate Response Measure (CRM) task and Institute of Electrical and Electronics Engineers (IEEE) sentences, each presented at two decibel signal-to-noise ratios (dB SNR). Results obtained at first study visit.
CRM at -9 dB SNR
Group
Value
95% CI
Pooled Participant Data
-0.18
CRM at -6 dB SNR
Group
Value
95% CI
Pooled Participant Data
0.28
IEEE at -6 dB SNR
Group
Value
95% CI
Pooled Participant Data
-0.06
IEEE at -3 dB SNR
Group
Value
95% CI
Pooled Participant Data
0.45
Change in Auditory Training Sentence Task PerformanceSecondary· First and last measurements (baseline and last session up to a year later)
Difference in percent correct of auditory training sentences, computed between first and last measurements.
Group
Value
95% CI
Training
3
-2 – 12
Change in Auditory Training Phoneme Task PerformanceSecondary· First and last measurements (baseline and last session up to a year later)
Difference in signal-to-noise ratio (in decibels) on auditory training phoneme tasks (onsets, nuclei, and codas), computed between first and last measurement.
Onsets
Group
Value
95% CI
Training
-4.38
-22.98 – -1.99
Nuclei
Group
Value
95% CI
Training
-2.99
-6.14 – 2.83
Codas
Group
Value
95% CI
Training
-2.60
-10.99 – 10.37
Association Between Medial Olivocochlear Reflex Inhibition and Slope of the Psychometric Function of Untrained Speech Perception TasksSecondary· Baseline (First study visit - 3 hour session)
Partial Spearman rank correlation computed between medial olivocochlear reflex inhibition (in decibels) and slope of the psychometric function (in decibel per decibel) of untrained speech tasks (Coordinate Response Measure -- CRM; Institute of Electrical and Electronics Engineers -- IEEE) obtained from performance across two signal-to-noise ratios. Age and high-frequency pure-tone average were controlled for in this post-hoc analysis. Results obtained at first study visit.
CRM Slope
Group
Value
95% CI
Pooled Participant Data
0.59
IEEE Slope
Group
Value
95% CI
Pooled Participant Data
0.60
Adverse events — posted to ClinicalTrials.gov
Time frame: Through study completion, maximum of 1 year..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to determine how changes in speech perception resulting from a computerized auditory training program are related to concurrent changes in auditory brainstem function resulting from the training. It is hypothesized that the degree of improvement in speech perception will be correlated with the degree of change in brainstem function.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VA Loma Linda Health Care System
Last refreshed: 5 January 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02574247.